Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sarepta Therapeutics Inc SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy... see more

NDAQ:SRPT - Post Discussion

Sarepta Therapeutics Inc > Buy Recommendation Issued On SRPT By Needham
View:
Post by whytestocks on Jun 21, 2024 10:45am

Buy Recommendation Issued On SRPT By Needham

JUST IN: $SRPT Buy Recommendation Issued On SRPT By Needham2024-06-21 10:15:03 ET Needham analyst issues BUY recommendation for SRPT on June 21, 2024 08:32AM ET. The previous analyst recommendation was Buy. SRPT was trading at $162.91 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...SRPT - Buy Recommendation Issued On SRPT By Needham
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities